UK-based biotechnology company Critical Pharmaceuticals is to collaborate with the University of Nottingham for the development of a nano-enabled intranasal formulation of teriparatide.
Funding worth £545,000 has been provided by the Technology Strategy Board and the Engineering and Physical Sciences Research Council to support the project, designed to create a technology-enabled treatment of osteoporosis.
Go deeper with GlobalData
Teriparatide is commonly used to treat osteoporosis but is currently administered through a daily injection.
The collaboration hopes to develop a nasal spray formulation of the drug, enabling patients to easily administer teriparatide themselves and enhance the drug’s overall efficacy.
Critical Pharmaceuticals hopes to use its CriticalSorb nanotechnology, a best in class absorption promoter that is currently being used alongside a nasal formulation of human growth hormone (CP024), currently in phase I clinical development.
Osteoporosis affects an estimated 75 million people across Europe, the US and Japan.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
